Translate AMICOR contents if you like

Thursday, July 28, 2016

methylene blue fails

Tau Drug Flops in Study

A derivative of methylene blue fails in phase III trial

  • Activate MedPage Today's CME feature and receive free CME credit on Medical stories like this one.

Action Points

TORONTO -- A derivative of methylene blue that's supposed to block tau aggregation in mild-to-moderate Alzheimer's disease failed in a phase III study, researchers reported here.

No comments: